---
title: "Wave Life Sciences and GSK Advance Oligonucleotide Therapeutics Collaboration"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274513654.md"
datetime: "2026-02-02T12:30:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274513654.md)
  - [en](https://longbridge.com/en/news/274513654.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274513654.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274513654.md) | [繁體中文](https://longbridge.com/zh-HK/news/274513654.md)


# Wave Life Sciences and GSK Advance Oligonucleotide Therapeutics Collaboration

Wave Life Sciences Ltd. and GSK continue their research collaboration, focusing on advancing novel oligonucleotide therapies using Wave’s PRISM® platform. In January 2026, GSK selected a fourth program to move forward to development candidate status under their partnership, which allows GSK to advance up to eight programs. Wave is eligible for up to $2.8 billion in milestone and royalty payments as these programs progress. The collaboration spans multiple therapy areas and remains active, with ongoing target validation work and anticipated milestone payments for Wave in 2026 and beyond. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9646790) on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [Wave Life Sciences Ltd. (WVE.US)](https://longbridge.com/en/quote/WVE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [GlaxoSmithKline plc (GSK.UK)](https://longbridge.com/en/quote/GSK.UK.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Virtus LifeSci Biotech Clinical Trls ETF (BBC.US)](https://longbridge.com/en/quote/BBC.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [State Street® SPDR® S&P® PhrmctlsETF (XPH.US)](https://longbridge.com/en/quote/XPH.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [GSK plc (GSK.US)](https://longbridge.com/en/quote/GSK.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [GSK RSV vaccine secures age indication expansion from US FDA](https://longbridge.com/en/news/279031789.md)
- [GSK gets US FDA approval for expanded use of RSV vaccine](https://longbridge.com/en/news/279030692.md)
- [FDA approves GSK’s Wellcovorin for cerebral folate deficiency](https://longbridge.com/en/news/278697677.md)
- [Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data](https://longbridge.com/en/news/278565911.md)
- [Trump expands drug discount push with two pharma heavy hitters joining TrumpRx](https://longbridge.com/en/news/279104094.md)